HER2+ breast cancer accounts for approximately 15%–20% of breast cancer, which is defined as high expression measured by immunohistochemistry status and/or amplification of HER2 detected by fluorescence in‐situ hybridization (FISH).5 This evidence concerns the gene ERBB2 and breast cancer.